Malignancies Clinical Trials

204 recruitingLast updated: June 18, 2026

There are 204 actively recruiting malignancies clinical trials across 56 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 3, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Shanghai, Shanghai Municipality, China. Updated daily from ClinicalTrials.gov.


Malignancies Trials at a Glance

204 actively recruiting trials for malignancies are listed on ClinicalTrialsFinder across 6 cities in 56 countries. The largest study group is Phase 1 with 107 trials, with the heaviest enrollment activity in Houston, New York, and Shanghai. Lead sponsors running malignancies studies include M.D. Anderson Cancer Center, Shenzhen Geno-Immune Medical Institute, and National Cancer Institute (NCI).

Browse malignancies trials by phase

Treatments under study

About Malignancies Clinical Trials

Looking for clinical trials for Malignancies? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignancies trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignancies clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 204 trials

Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 1

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies

Advanced Malignancies
Novartis Pharmaceuticals24 enrolled3 locationsNCT07340190
Recruiting
Not Applicable

Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Patients Receiving Oral Treatment for Cancer or Malignant Haemopathy (ACCELER PLATFORM)

Solid CancerHaematological Malignancies
Institut Claudius Regaud33 enrolled1 locationNCT06797037
Recruiting

An Exploratory Study on Microbial Biomarkers Associated With the Efficacy of Neoadjuvant Therapy

Digestive System Malignancies
Tianjin Medical University Cancer Institute and Hospital90 enrolled1 locationNCT07263620
Recruiting
Phase 2

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Chronic Lymphocytic LeukemiaB-cell Malignancies
Curis, Inc.108 enrolled11 locationsNCT07271667
Recruiting
Phase 1

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Myelodysplastic SyndromesRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AML+1 more
Institut de Recherches Internationales Servier291 enrolled30 locationsNCT02074839
Recruiting
Phase 3

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled782 locationsNCT03486873
Recruiting
Phase 3

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Solid TumorHematologic MalignancyAdvanced Malignancies
Novartis Pharmaceuticals50 enrolled15 locationsNCT06401356
Recruiting
Phase 2

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 1Phase 2

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

Myeloid MalignanciesLymphodepleting Chemotherapy
M.D. Anderson Cancer Center44 enrolled1 locationNCT06383572
Recruiting
Phase 1

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.85 enrolled9 locationsNCT06980116
Recruiting
Phase 1

Radiologic Pathologic Correlation of Imaging to Distinguish True Progression From Pseudoprogression in Brain Malignancies

Brain MalignanciesPseudoprogression
M.D. Anderson Cancer Center25 enrolled1 locationNCT06199479
Recruiting

A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy

Secondary Malignancies of T-cell Origin
Novartis Pharmaceuticals30 enrolled4 locationsNCT07378969
Recruiting
Not Applicable

Liver Volume Variation Effect on SBRT Planning and Delivery for Upper Abdominal Malignancies

Upper Abdominal Malignancies
University of Pittsburgh17 enrolled1 locationNCT06355895
Recruiting
Phase 1Phase 2

Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies

Advanced Malignancies
PharmaMar119 enrolled6 locationsNCT07644039
Recruiting
Not Applicable

Laparotomy vs Laparoscopy in Endometrial Cancer Staging

LaparoscopicGynaecological MalignanciesGynaecological Oncology
Assiut University48 enrolled1 locationNCT07546825
Recruiting
Phase 1Phase 2

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

Hematologic MalignanciesHIV
National Cancer Institute (NCI)265 enrolled1 locationNCT05470491
Recruiting
Phase 1

Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment

Advanced Malignancies and Hepatic Impairment
Novartis Pharmaceuticals24 enrolled5 locationsNCT07422610
Recruiting
Phase 2

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Hematological Malignancies
Janssen Research & Development, LLC510 enrolled78 locationsNCT04634552
Recruiting
Phase 1

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

Hematologic NeoplasmsHematologic Malignancies
National Cancer Institute (NCI)155 enrolled1 locationNCT07162038